Cargando…

(2R,3S)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia

SIMPLE SUMMARY: Acute myeloid leukemia (AML) is one of several cancers where cancer proliferation occurs under the influence of an aberrant metabolite known as an oncometabolite produced by a mutated enzyme in the cancer cell. In AML, mutant isocitrate dehydrogenases produce the oncometabolite 2-hyd...

Descripción completa

Detalles Bibliográficos
Autores principales:	Idle, Jeffrey R., Seipel, Katja, Bacher, Ulrike, Pabst, Thomas, Beyoğlu, Diren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600928/ https://www.ncbi.nlm.nih.gov/pubmed/33019704 http://dx.doi.org/10.3390/cancers12102842

Ejemplares similares

The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features
por: Pabst, Thomas, et al.
Publicado: (2017)

Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2019)

HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2023)

Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2022)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
por: Liu, Xiaoyan, et al.
Publicado: (2019)

Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy
por: Beyoğlu, Diren, et al.
Publicado: (2020)

Metabolic Rewiring and the Characterization of Oncometabolites
por: Beyoğlu, Diren, et al.
Publicado: (2021)

Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias
por: Testa, Ugo, et al.
Publicado: (2020)

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
por: DiNardo, Courtney D., et al.
Publicado: (2021)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

A Novel Anti-Hepatitis C Virus and Antiproliferative Agent Alters Metabolic Networks in HepG2 and Hep3B Cells
por: Keogh, Adrian, et al.
Publicado: (2017)

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis
por: OHBA, Shigeo, et al.
Publicado: (2016)

Robust Regression Analysis of GCMS Data Reveals Differential Rewiring of Metabolic Networks in Hepatitis B and C Patients
por: Simillion, Cedric, et al.
Publicado: (2017)

Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia
por: Kövy, Petra, et al.
Publicado: (2021)

Metabolic Hijacking of Hexose Metabolism to Ascorbate Synthesis Is the Unifying Biochemical Basis of Murine Liver Fibrosis
por: Beyoğlu, Diren, et al.
Publicado: (2023)

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
por: Golub, Danielle, et al.
Publicado: (2019)

The metabolomic profile of gamma-irradiated human hepatoma and muscle cells reveals metabolic changes consistent with the Warburg effect
por: Wang, Min, et al.
Publicado: (2016)

Hepatitis C Virus Infection Upregulates Plasma Phosphosphingolipids and Endocannabinoids and Downregulates Lysophosphoinositols
por: Beyoğlu, Diren, et al.
Publicado: (2023)

A Metabolomic Analysis of Cirrhotic Ascites
por: Beyoğlu, Diren, et al.
Publicado: (2022)

Isocitrate Dehydrogenase 1 Mutation and Ivosidenib in Patients With Acute Myeloid Leukemia: A Comprehensive Review
por: Tangella, Adarsh Vardhan, et al.
Publicado: (2023)

Adult isocitrate dehydrogenase–mutant brainstem glioma: illustrative case
por: Ye, Vincent C., et al.
Publicado: (2021)

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
por: Gallus, Marco, et al.
Publicado: (2023)

Autologous Transplantation for Older Adults with AML
por: Mueller, Beatrice U., et al.
Publicado: (2018)

Bone Marrow Features in Patients With Acute Myeloid Leukemia Treated With Novel Targeted Isocitrate Dehydrogenase 1/2 Inhibitors
por: Hagiya, Ashley, et al.
Publicado: (2019)

Short-Term Grape Consumption Diminishes UV-Induced Skin Erythema
por: Pezzuto, John M., et al.
Publicado: (2022)

Influence of grape consumption on the human microbiome
por: Dave, Asim, et al.
Publicado: (2023)

Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia
por: Boutzen, Héléna, et al.
Publicado: (2016)

Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations
por: Berger, Raffaela S., et al.
Publicado: (2019)

Photoactivation of Mutant Isocitrate Dehydrogenase 2 Reveals Rapid Cancer-Associated Metabolic and Epigenetic Changes
por: Walker, Olivia S., et al.
Publicado: (2016)

Oncogenic transgelin-2 is differentially regulated in isocitrate dehydrogenase wild-type vs. mutant gliomas
por: Beyer, Sasha J., et al.
Publicado: (2018)

Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents
por: Khalil, Ahmed F., et al.
Publicado: (2023)

MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
por: Seipel, Katja, et al.
Publicado: (2018)

Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia
por: Alkhatabi, Heba, et al.
Publicado: (2021)

Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases: Synthesis, Structure–Activity Relationship, and Selective Antitumor Activity
por: Liu, Zhen, et al.
Publicado: (2014)

Activation of Vitamin D Receptor Pathway Enhances Differentiating Capacity in Acute Myeloid Leukemia with Isocitrate Dehydrogenase Mutations
por: Sabatier, Marie, et al.
Publicado: (2021)

Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia
por: Willander, Kerstin, et al.
Publicado: (2014)

Identification of a New Selective Chemical Inhibitor of Mutant Isocitrate Dehydrogenase-1
por: Kim, Hyo-Joon, et al.
Publicado: (2015)

Gemistocytic Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A Histopathological and Survival Analysis
por: Hassan, Usman, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kcmc7udek25ljmuh46n9nuqv8b